Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Simple Search

Search Type: Criteria:

You could also try: disruptive (8), unhelpful (9), awkward (2)

Long-term continuous positive airway pressure (CPAP) treatment - patient information

Description: This leaflet explains what obstructive sleep apnoea (OSA) is, what long-term continuous positive airway pressure (CPAP) treatment for OSA involves
Url: /Media/UHS-website-2019/Patientinformation/Respiratory/Long-term-continuous-positive-airway-pressure-CPAP-treatment-3385-PIL.pdf

Prof Tom Wilkinson, research lead for airways diseases

Description: NIHR Southampton Biomedical Research Centre Auto Generated Title Prof Tom Wilkinson is a clinician and researcher interested in asthma and chronic obst
Url: /ClinicalResearchinSouthampton/Our-people/Respiratory-research-people/Prof-Tom-Wilkinson-research-lead-for-airways-diseases.aspx

GP referral for the adult sleep service (Word)

Description: Referral to the Adult Sleep Service * Referrals must be sent via the e-Referrals System (e-RS). Please attach this form, as well as any other relevant
Url: /Media/UHS-website-2019/Docs/Services/Respiratory/Sleep-service/GP-referral-for-the-adult-sleep-service-Word.docx

DVdSC (weekly cycles 9 onwards) DaratumumabSC-Bortezomib-Dexamethasone Ver1

Description: Chemotherapy Protocol Myeloma DVd SC (weekly) Bortezomib Daratumumab Dexamethasone Cycles 9 onwards Regimen • Myeloma – Bortezomib with daratumumab and dexameth
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DVdSC-weekly-cycles-9-onwards-DaratumumabSC-Bortezomib-Dexamethasone-Ver1.pdf

Daratumumab SC Ver1

Description: Chemotherapy Protocol Myeloma Daratumumab Subcutaneous Regimen • Myeloma – Daratumumab (SC) Indication • Daratumumab monotherapy is recommended as an option for tr
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/Daratumumab-SC-Ver1.pdf

DRD Daratumumab-Lenalidomide-Dexamethasone

Description: Chemotherapy Protocol Myeloma DRD Daratumumab-Lenalidomide-Dexamethasone Regimen • Myeloma – DRD Daratumumab-Lenalidomide-Dexamethasone Indication • Daratumumab in
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DRD-Daratumumab-Lenalidomide-Dexamethasone.pdf

DVd-T SC Bortezomib-Daratumumab-Dexamethasone-Thalidomide v1

Description: Details of the Chemotherapy Protocol for Myeloma.
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DVd-T-SC-Bortezomib-Daratumumab-Dexamethasone-Thalidomide.pdf

DVdSC (weekly cycles1-8) Bortezomib-Daratumumab-Dexamethasone Ver1

Description: Chemotherapy Protocol Myeloma DVd SC (weekly cycles 1-8) Bortezomib-Daratumumab-Dexamethasone Regimen • Myeloma – DVd SC (weekly cycles 1-8) bortezomib-daratumumab
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DVdSC-weekly-cycles1-8-Bortezomib-Daratumumab-Dexamethasone-Ver1.pdf

Featured research: fighting lung disease

Description: Auto Generated Title Southampton researchers are looking for healthy people between 60 and 85 years of age to take part in a
Url: /ClinicalResearchinSouthampton/Public-and-patients/Featured-research-studies/Featured-research-fighting-lung-disease.aspx

UHS AR 22-23-6

Description: 2022/23 Incorporating the quality account University Hospital Southampton NHS Foundation Trust Annual Report and Accounts 2022/23 Presented to Parliament
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Annual-reports-and-quality-accounts/UHS-AR-22-23-6.pdf

1 to 10 of 33

Previous 1 2 3 4 Next